Spectral Medical Inc. (EDTXF)

Market Cap	166.30M
Revenue (ttm)	1.59M
Net Income (ttm)	-10.70M
Shares Out	n/a
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38,000
Average Volume	14,301
Open	0.5794
Previous Close	0.5640
Day's Range	0.5640 - 0.5794
52-Week Range	0.3170 - 0.6060
Beta	0.52
RSI	62.47
Earnings Date	Mar 27, 2025

About Spectral Medical

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac prot...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1991
• Employees: 29
• Stock Exchange: OTCMKTS
• Ticker Symbol: EDTXF

Financial Performance

In 2024, Spectral Medical's revenue was 2.29 million, an increase of 43.05% compared to the previous year's 1.60 million. Losses were -15.40 million, -1.66% less than in 2023.

Financial numbers in CAD